使用因残疾而调整的寿命年来比较医学诊断辐射暴露的益处和危害:朝着定量证明的方向
1Visiting Research Fellow Institute of Health University of Cumbria, Lancaster, United Kingdom.
概括
量化医疗辐射的益处与损害是具有挑战性的,特别是对于非致命性疾病. 这项研究提出了一种使用残疾调整寿命年 (DALYs) 的新理由因子,以改善患者的辐射保护.
科学领域:
- 医学物理 医学物理
- 辐射保护 辐射保护
- 公共卫生 公共卫生
背景情况:
- 医疗辐射暴露的合理性要求益处超过损害.
- 量化利益损害评估是很困难的,特别是对于非致命的条件.
- 根据残疾调整的寿命年 (DALY) 是疾病严重程度的公共卫生指标.
研究的目的:
- 探索用于量化医疗辐射合理性的益处和危害的方法.
- 评估DALYs用于测量辐射损害的使用.
- 为放射学程序提出一个新的理由因素.
主要方法:
- 审查DALYs作为辐射损害的衡量标准.
- 对各种疾病的确定的DALY值的分析.
- 根据利益和损害变化速率,制定和评估一个拟议的证明因素.
主要成果:
- 使用统计生命表计算理由因子的现有方法存在局限性.
- 提出了一个建议的证明因子,计算为福利变化率除以损害变化率的变化率.
- 这一因素与年龄无关,适用于非致命性疾病.
结论:
- 拟议的证明因子为评估医疗辐射暴露提供了一个简单,逻辑和道德的方法.
- 它为接受放射性手术的患者提供了更清晰的风险和益处解释.
- 这种方法通过提供更强大的理由框架来增强患者的辐射保护.
更多相关视频
10:33Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
Published on: September 4, 2017
15.8K
06:21Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
Published on: May 27, 2016
8.1K
相关概念视频
Biological Effects of Radiation
15.5K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
15.5K
Comparing the Survival Analysis of Two or More Groups
197
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
197
X-ray Imaging
5.5K
German physicist Wilhelm Röntgen (1845–1923) was experimenting with electrical current when he discovered that a mysterious and invisible "ray" would pass through his flesh but leave an outline of his bones on a screen coated with a metal compound. In 1895, Röntgen made the first durable record of the internal parts of a living human: an "X-ray" image (as it came to be called) of his wife’s hand. Scientists worldwide quickly began their own experiments with...
5.5K
Statistical Methods for Analyzing Epidemiological Data
372
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
372
Relative Risk
183
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
183
Hazard Ratio
130
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
130
